Neuigkeiten

Neuigkeiten aus dem GMP-Umfeld und von der Valicare GmbH

Nachrichten aus aller Welt

Unser internationaler Pressespiegel zeigt eine Auswahl an Nachrichten und neusten Artikel zu den Themen Arzneimittel neuartiger Therapien (ATMP), Chimäre Antigenrezeptor(CAR)-T-Zell-Therapie, Tumor infiltrierende Lymphozyten (TIL) und biotechnologisch bearbeitete Gewebeprodukte (TEP).

FDA Updates for the Week of October 11, 2021

16.10.2021 | Managed Healthcare Executive

In COVID-19 news: An advisory committee recommends both J&J's and Moderna’s booster, Regeneron seeks full approved for its treatment and ...

New strides in H2O2 biodecontamination

15.10.2021 | Cleanroom Technology

Since the emergence of ‘isolator technology’ in the 1980s, hydrogen peroxide has been the favoured agent for biodecontamination because the ...

EMA starts rolling review of AstraZeneca antibody cocktail to prevent COVID-19

14.10.2021 | FirstWord Pharma

HomePartner Showcase Register Free Trial Contact Us Advertise My NewsMy CompanyWatch My ConditionWatch My ...

Friday Five – The Pharma Week in Review (15 October 2021)

14.10.2021 | FirstWord Pharma

HomePartner Showcase Register Free Trial Contact Us Advertise My NewsMy CompanyWatch My ConditionWatch My ...

Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives

14.10.2021 | Science Direct

Highlights • Tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-redirected T cells and chimeric antigen receptor (CAR)-engineered ...

New CAR T-Cell Therapy Appears Safe in B-Cell Malignancies

13.10.2021 | Targeted Oncology

CTX100, an allogeneic chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD19-positive B-cell ...

Thinking About Risk Early on Is Key for Cell Therapy Success

13.10.2021 | Labiotech.eu

NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma

13.10.2021 | Le Lezard (EN)

The Benefit of CAR T-Cell Therapy in Indolent Lymphoma

12.10.2021 | Oncology - CancerNetwork

Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.

A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy

11.10.2021 | CURE

Bob Schulz knew something was wrong when he had a hard time walking up the hill while golfing in December 2018. At 73, he still walked the ...

US FDA approves Enzyvant’s Rethymic, a one-time regenerative tissue-based therapy for pediatric congenital athymia

11.10.2021 | Pharmabiz.com

Enzyvant announced the US Food and Drug Administration (FDA) approval of Rethymic (allogeneic processed thymus tissue-agdc), a one-time ...

Alternative zu ELISA: Echtzeitanalyse von Protein-Protein Interaktionen

10.10.2021 | LaborPraxis - Vogel Business Media

COVID-19 research news in brief

10.10.2021 | Insight Plus

From the New England Journal of MedicineEffectiveness of mRNA COVID-19 vaccine among US health care personnel: “The ...

FDA Updates for the Week of Oct. 4, 2021

09.10.2021 | Managed Healthcare Executive

Pfizer officially seeks EUA for pediatric COVID vaccine, AstraZeneca seeks EU for COVID-19 prevention, J&J submits data for COVID-19 ...

Nerve repair, with help from stem cells

09.10.2021 | Biz News Post

Faced with repairing a major nerve injury to the face or mouth, skilled surgeons can take a nerve from an arm or leg and use to it restore ...

Wir sind für Sie da

Kontaktieren Sie uns, wenn Sie Fragen haben. Wir antworten und beraten Sie gerne. 

Kontakt